Floatz logo

Rituximab

Post-Transplant Lymphoproliferative Disease

Jennifer Amengualmonoclonal_antibodyPhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Post-Transplant Lymphoproliferative Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Washington University School of Medicine
Phase 2BBB
Fludarabine
City of Hope Medical Center
Phase 2BB
Cyclosporin A
National Cancer Institute (NCI)
Phase 2BB
Methotrexate
National Cancer Institute (NCI)
Phase 2BB
Lenalidomide
Northwestern University
Phase 2B

View all 47 →

Same molecule, other indications

Rituximab is also rated in:

lymphoblastic lymphomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
grade III lymphomatoid granulomatosisDormant
BBB
Indicative · Phase 2
74 / 100
View asset →
testicular lymphomaDormant
BBB
Indicative · Phase 2
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →